GlassScriptPhysician profile
Kevin Ende
NPI 1528285335
$5,748.29
in general payments reported to CMS, 2019-2025
22 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Plastic Surgery Within The Head & Neck providers received nationally (typical 2025 total: $238).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.99 · 2020: $225 · 2021: $732 · 2022: $409 · 2023: $478 · 2024: $2,827 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334 · Travel and Lodging: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.79 |
| Travel and Lodging | $1,032.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $3,028.39 | 2021-2025 | |
| Acclarent, INC | $445.20 | 2021-2024 | Acclarent Aera, Acclarent Navwire |
| Optinose US, INC. | $344.52 | 2024-2025 | |
| Genzyme Corporation | $335.11 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.37 | 2024-2025 | Dupixent |
| Allergan, INC. | $195.16 | 2021 | |
| Intersect Ent, INC. | $188.17 | 2020-2022 | |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Stryker Corporation | $141.22 | 2020-2025 | Xpress Loprofile |
| Alk-Abello, INC | $133.74 | 2020-2024 | Grastek, Odactra, Ragwitek |
| Grifols USA, LLC | $115.81 | 2025 | Xembify |
| Integra Lifesciences Corporation | $104.76 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Glaukos Corporation | $93.07 | 2022 | |
| Medtronic, INC. | $33.00 | 2021 | |
| Pentax of America, INC. | $30.55 | 2024 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.80 | 2024 | Xolair |
| Precigen, INC. | $16.68 | 2025 | |
| Glaxosmithkline, LLC. | $16.40 | 2024 | Nucala |
| Abbvie INC. | $15.52 | 2023 | |
| Eyevance Pharmaceuticals LLC | $14.99 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.99 | 2019 | |
| Oyster Point Pharma, INC. | $13.84 | 2025 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.